EFM
GLUE icon

E Fund Management’s Monte Rosa Therapeutics GLUE Stock Holding History

E Fund Management’s Portfolio GLUE Stock Details GLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$216K Buy
+13,151
New +$251K 0.01% 439

Other funds holding GLUE

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

E Fund Management's GLUE Position: Q1 2026 in Review

E Fund Management opened a new position in Monte Rosa Therapeutics (GLUE) in Q1 2026: 13,151 shares worth $216K. The stake represents 0.01% of the portfolio and ranks #439 among its holdings.

190 funds tracked by Wall St. Rank hold GLUE as of Q1 2026.

  • E Fund Management held 13,151 shares of Monte Rosa Therapeutics worth $216K as of Q1 2026.
  • Monte Rosa Therapeutics was a new E Fund Management position in Q1 2026.
  • Monte Rosa Therapeutics made up 0.01% of E Fund Management's portfolio in Q1 2026, its #439 holding.
  • 190 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q1 2026.

Based on E Fund Management's 13F filing for Q1 2026, filed 13 Apr 2026.